Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9H6L2
UPID:
TM231_HUMAN
Alternative names:
-
Alternative UPACC:
Q9H6L2; A0JLU1; A6NDZ6; B3KU85; G5E9E3; Q6P450; Q6UWW5
Background:
Transmembrane protein 231 plays a pivotal role in the formation and function of primary cilia, serving as a transmembrane component of the tectonic-like complex. This complex is crucial for ciliogenesis and the sonic hedgehog signaling pathway, which are essential for the proper development and function of various organs.
Therapeutic significance:
Transmembrane protein 231 is implicated in Joubert syndrome 20 and Meckel syndrome 11, both of which involve developmental anomalies and organ dysfunctions. Understanding the role of Transmembrane protein 231 could open doors to potential therapeutic strategies for these complex disorders.